Clozapine STADA: Uses, Dosage & Side Effects
Atypical antipsychotic for treatment-resistant schizophrenia
Quick Facts About Clozapine STADA
Key Takeaways
- Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, with response rates of 30-60% in patients who have failed other medications.
- Mandatory blood monitoring is required due to the risk of agranulocytosis (severe neutropenia), occurring in approximately 0.8% of patients.
- It is the only antipsychotic approved for reducing suicidal behavior in schizophrenia and schizoaffective disorder.
- Common side effects include sedation, weight gain, increased salivation, constipation, and metabolic changes that require ongoing monitoring.
- Treatment must never be stopped abruptly; gradual dose reduction under medical supervision is essential to prevent rebound symptoms and psychotic relapse.
What Is Clozapine STADA and What Is It Used For?
Clozapine STADA belongs to a class of medications known as atypical (second-generation) antipsychotics, specifically within the dibenzodiazepine chemical family. The active ingredient, clozapine, was first synthesized in 1958 and introduced into clinical use in the 1970s. Although it was temporarily withdrawn in some markets due to concerns about agranulocytosis, it was reintroduced with mandatory blood monitoring programs and has since become one of the most important medications in psychiatric practice.
Clozapine works by blocking multiple neurotransmitter receptors in the brain, including dopamine D1, D2, D3, and D4 receptors, serotonin 5-HT2A and 5-HT2C receptors, muscarinic receptors, histamine H1 receptors, and adrenergic alpha-1 receptors. This unique and broad receptor binding profile distinguishes clozapine from all other antipsychotics and is thought to explain both its superior efficacy in treatment-resistant cases and its relatively lower risk of causing movement disorders (extrapyramidal symptoms).
The primary indication for Clozapine STADA is treatment-resistant schizophrenia, defined as a failure to respond adequately to at least two different antipsychotic medications given at appropriate doses for sufficient duration (typically 6-8 weeks each). According to the National Institute for Health and Care Excellence (NICE) guidelines, clozapine should be offered to all patients who meet these criteria, as delaying clozapine initiation is associated with poorer long-term outcomes.
Clozapine is also the only antipsychotic with proven anti-suicidal properties. The landmark InterSePT trial demonstrated that clozapine significantly reduces suicidal behavior compared to olanzapine in patients with schizophrenia or schizoaffective disorder at high risk of suicide. This has led to a specific approved indication for reducing the risk of recurrent suicidal behavior.
Additional uses, sometimes prescribed off-label under specialist supervision, include treatment of psychosis in Parkinson's disease (when other approaches have failed), severe treatment-resistant bipolar disorder, and aggressive or self-injurious behavior in patients with intellectual disabilities. In all cases, the benefits must be carefully weighed against the risks, and treatment should be initiated and monitored by psychiatrists experienced with clozapine therapy.
What Should You Know Before Taking Clozapine STADA?
Clozapine is a powerful medication that requires thorough medical evaluation before treatment can begin. Your prescribing psychiatrist will conduct a comprehensive assessment including blood tests, cardiovascular evaluation, and a review of your complete medical history. Understanding the contraindications, precautions, and monitoring requirements is essential for safe treatment.
Contraindications
Clozapine STADA must not be used in the following situations:
- Hypersensitivity to clozapine or any of the excipients in the tablet formulation
- History of clozapine-induced agranulocytosis or severe neutropenia (unless the cause was clearly identified as non-clozapine related)
- Myeloproliferative disorders or a history of toxic or idiosyncratic granulocytopenia/agranulocytosis (excluding chemotherapy-induced)
- Active bone marrow disorder or conditions that impair bone marrow function
- Uncontrolled epilepsy as clozapine lowers the seizure threshold in a dose-dependent manner
- Severe hepatic disease or active liver disease with symptoms such as nausea, jaundice, or elevated liver enzymes
- Paralytic ileus as clozapine has strong anticholinergic properties that can worsen bowel obstruction
- Severe renal impairment requiring dialysis
- Severe cardiac disease including active myocarditis, cardiomyopathy, or decompensated heart failure
- Concurrent use of medications known to cause agranulocytosis, such as carbamazepine, clozapine-incompatible chemotherapy agents, or long-acting depot antipsychotics (which cannot be rapidly withdrawn if neutropenia develops)
Warnings and Precautions
Beyond the risk of neutropenia, several other important warnings apply to clozapine therapy:
- Myocarditis and cardiomyopathy: Cases of potentially fatal myocarditis have been reported, predominantly in the first 2 months of treatment. Symptoms include unexplained fatigue, dyspnea, tachycardia, fever, chest pain, and palpitations. Immediate cardiac evaluation is required if these occur.
- Metabolic effects: Clozapine is associated with significant weight gain, hyperglycemia (including new-onset diabetes), and dyslipidemia. Regular monitoring of weight, fasting glucose, and lipid profiles is essential.
- Seizures: The risk of seizures is dose-dependent, estimated at approximately 1% at doses below 300 mg/day, 2.7% at 300-599 mg/day, and 4.4% at 600 mg/day or above. Dose increases should be gradual.
- Sedation and cognitive impairment: Particularly prominent during initiation and dose escalation. Patients should be cautioned about driving and operating machinery.
- Orthostatic hypotension: Can be severe, especially during initial titration. Rarely, collapse with cardiac or respiratory arrest has occurred.
- Constipation: Can progress to serious complications including ileus, bowel obstruction, fecal impaction, and intestinal ischemia, some of which have been fatal. Proactive bowel management is recommended.
- Venous thromboembolism: An increased risk of pulmonary embolism and deep vein thrombosis has been observed. Patients should be assessed for risk factors.
- QT prolongation: Although less than some other antipsychotics, caution is warranted in patients with cardiac risk factors or those taking other QT-prolonging medications.
Pregnancy and Breastfeeding
Clozapine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal studies have not shown teratogenic effects, but there are limited data from human pregnancies. Neonates exposed to antipsychotics during the third trimester are at risk of extrapyramidal symptoms and withdrawal symptoms after delivery, which may vary in severity and duration.
Women of childbearing potential should use effective contraception during treatment. If pregnancy occurs during clozapine therapy, the decision to continue or discontinue treatment should be made on an individual basis, weighing the risks of untreated psychosis against the potential risks to the fetus. Abrupt discontinuation should be avoided due to the risk of rapid psychotic relapse.
Clozapine is excreted into breast milk. Breastfeeding is generally not recommended during clozapine treatment due to the potential for serious adverse effects in the nursing infant, including sedation, feeding difficulties, and hematological effects. If a decision is made to breastfeed, close monitoring of the infant is essential.
How Does Clozapine STADA Interact with Other Drugs?
Clozapine is primarily metabolized by the cytochrome P450 enzymes CYP1A2 and CYP3A4, with minor contributions from CYP2C19 and CYP2D6. Any medication that significantly inhibits or induces these enzymes can alter clozapine plasma levels, potentially leading to toxicity or loss of efficacy. Additionally, clozapine's pharmacodynamic properties mean it can interact with many other centrally acting drugs. Understanding these interactions is critical for safe prescribing.
Major Interactions
| Interacting Drug | Effect | Clinical Significance | Management |
|---|---|---|---|
| Fluvoxamine | Potent CYP1A2 inhibitor; can increase clozapine levels 5-10 fold | High risk of clozapine toxicity including seizures and sedation | Avoid combination or reduce clozapine dose by up to 2/3 with intensive monitoring |
| Ciprofloxacin | Moderate CYP1A2 inhibitor; increases clozapine levels 2-3 fold | Significant risk of toxicity during antibiotic course | Use alternative antibiotic; if unavoidable, reduce clozapine dose and monitor levels |
| Carbamazepine | Potent CYP3A4/CYP1A2 inducer; reduces clozapine levels. Also causes agranulocytosis. | Contraindicated: additive bone marrow suppression risk and reduced efficacy | Absolutely contraindicated. Use valproate or lamotrigine as alternatives. |
| Phenytoin | CYP3A4 inducer; may reduce clozapine levels | Loss of antipsychotic efficacy possible | Monitor clozapine levels; consider alternative anticonvulsants |
| Benzodiazepines | Additive CNS depression and respiratory depression | Rare cases of cardiovascular or respiratory collapse, especially during initiation | Use with extreme caution; start with low doses of both agents |
Minor Interactions
| Interacting Drug | Effect | Management |
|---|---|---|
| Caffeine | CYP1A2 substrate competition; may modestly increase clozapine levels | Maintain consistent caffeine intake; sudden changes can affect levels |
| SSRIs (sertraline, paroxetine, fluoxetine) | Variable CYP2D6/CYP1A2 inhibition; modest increases in clozapine levels | Monitor for side effects; sertraline is generally the safest SSRI to combine |
| Lithium | Possible additive neurotoxic effects; increased risk of seizures and NMS | Monitor for neurotoxicity; check lithium and clozapine levels regularly |
| Omeprazole | CYP1A2 inducer at high doses; may modestly reduce clozapine levels | Monitor for reduced efficacy if starting or stopping omeprazole |
| Smoking (tobacco) | Polycyclic aromatic hydrocarbons in smoke strongly induce CYP1A2; reduces clozapine levels by up to 50% | Adjust dose if patient starts or stops smoking; clozapine levels can change rapidly |
What Is the Correct Dosage of Clozapine STADA?
Clozapine dosing must be individualized and follows a mandatory slow titration schedule to minimize the risk of orthostatic hypotension, seizures, and excessive sedation. The starting dose, titration speed, and target dose all depend on individual patient factors. Your psychiatrist will determine the optimal dose based on clinical response and tolerability, guided by therapeutic drug monitoring (clozapine blood levels).
Adults
Standard Adult Dosing Schedule
- Day 1: 12.5 mg once or twice daily
- Day 2: 25 mg once or twice daily
- Days 3-7: Increase by 25-50 mg per day as tolerated
- Weeks 2-3: Continue increasing by 25-50 mg every few days
- Target dose: 200-450 mg/day, usually divided into 2-3 doses
- Maximum dose: 900 mg/day (rarely needed; higher risk of seizures)
- Therapeutic blood level: 350-600 ng/mL (trough level, measured 12 hours after last dose)
The largest portion of the daily dose should be given at bedtime to take advantage of the sedative effect and minimize daytime drowsiness. Most patients achieve a stable dose within 2-4 weeks, though some may require further optimization over several months.
Children and Adolescents
Pediatric Dosing (Under 18 Years)
Clozapine use in children and adolescents under 18 years is generally off-label and should only be initiated by specialist child and adolescent psychiatrists. When used, an even more cautious titration is recommended:
- Starting dose: 12.5 mg once daily
- Titration: Increase by 12.5-25 mg every 1-2 days as tolerated
- Typical target dose: 150-300 mg/day
- Young patients may be more susceptible to metabolic side effects and sedation
Elderly
Geriatric Dosing (Over 65 Years)
Elderly patients require lower starting doses and slower titration due to increased sensitivity to anticholinergic effects, orthostatic hypotension, and sedation:
- Starting dose: 12.5 mg once daily
- Titration: Increase by 12.5-25 mg every 2-3 days
- Target dose: Often lower than in younger adults (100-300 mg/day)
- Increased risk of falls due to orthostatic hypotension and sedation
- Enhanced monitoring for cardiac effects and metabolic changes recommended
Missed Dose
If you miss a dose, take it as soon as you remember, unless it is nearly time for your next dose. In that case, skip the missed dose and continue with your regular schedule. Never take a double dose to make up for a missed one.
Overdose
Clozapine overdose is a medical emergency. Symptoms may include altered consciousness ranging from sedation to deep coma, tachycardia, hypotension, respiratory depression, aspiration pneumonia, cardiac arrhythmias, seizures, hypersalivation, and delirium. The lethal dose varies widely between individuals, but deaths have been reported with doses as low as 2,500 mg. However, some patients have survived ingestions exceeding 10,000 mg with appropriate intensive care management.
If overdose is suspected, call emergency services immediately. There is no specific antidote for clozapine. Treatment is supportive and may include gastric lavage (if within 1 hour of ingestion), activated charcoal, cardiovascular monitoring, airway management, and seizure control. Dialysis is not effective for removing clozapine from the body due to its high protein binding and large volume of distribution.
What Are the Side Effects of Clozapine STADA?
Like all medications, clozapine can cause side effects. Understanding the frequency and nature of these effects helps patients and caregivers recognize important symptoms early and seek appropriate medical attention when needed. Many side effects are dose-related and may improve with dose adjustment or targeted management strategies.
Very Common (affects more than 1 in 10 people)
- Drowsiness and sedation (especially early in treatment)
- Dizziness
- Tachycardia (fast heart rate)
- Constipation
- Hypersalivation (excessive salivation, particularly at night)
- Weight gain
- Nausea
Common (affects 1 in 10 to 1 in 100 people)
- Leukocytosis (elevated white blood cell count)
- Eosinophilia (elevated eosinophils)
- Headache
- Tremor
- Rigidity and akathisia (less frequent than with typical antipsychotics)
- Blurred vision
- Orthostatic hypotension (drop in blood pressure on standing)
- Hypertension
- Dry mouth
- Vomiting
- Urinary incontinence or retention
- Elevated liver enzymes
- Fatigue
- Fever (benign and transient in first weeks)
Uncommon (affects 1 in 100 to 1 in 1,000 people)
- Agranulocytosis (severe neutropenia; detected by monitoring)
- Seizures (dose-dependent; ~1% at doses <300 mg/day)
- Myocarditis (inflammation of the heart muscle)
- Dysphagia (difficulty swallowing)
- Hepatitis
- Pancreatitis
- Obsessive-compulsive symptoms
Rare (affects fewer than 1 in 1,000 people)
- Cardiomyopathy (disease of the heart muscle)
- Neuroleptic malignant syndrome (NMS)
- Pulmonary embolism and deep vein thrombosis
- Intestinal obstruction, ileus, fecal impaction
- Diabetic ketoacidosis
- Sudden cardiac death
- Pericarditis and pericardial effusion
- Tardive dyskinesia (very rare compared to typical antipsychotics)
It is important to note that many patients tolerate clozapine well and that the side effects listed above do not occur in every individual. Your psychiatrist and treatment team will work with you to manage side effects proactively, using strategies such as dose adjustment, timing of doses, and adjunctive medications where appropriate. The benefits of clozapine in treatment-resistant schizophrenia typically far outweigh the risks when the medication is properly monitored and managed.
How Should You Store Clozapine STADA?
Proper storage of Clozapine STADA is essential to maintain the medication's effectiveness and safety throughout its shelf life. Clozapine tablets should be stored at controlled room temperature, ideally below 25°C (77°F). Brief excursions to temperatures up to 30°C (86°F) are generally acceptable, but prolonged exposure to heat or humidity should be avoided.
Keep the tablets in their original blister packaging until you are ready to take them. This protects the medication from light and moisture, both of which can degrade the active ingredient. Do not transfer tablets to other containers unless they are specifically designed for medication storage with adequate moisture protection.
As with all medications, store Clozapine STADA out of the sight and reach of children. Because clozapine is a potent medication with serious effects, accidental ingestion by a child could be particularly dangerous. If accidental ingestion occurs, seek emergency medical attention immediately.
Do not use Clozapine STADA after the expiry date printed on the packaging. Expired medication may have reduced potency and should be returned to your pharmacy for proper disposal. Do not dispose of medications in household waste or wastewater, as this can contaminate the environment. Most pharmacies offer safe medication disposal services.
What Does Clozapine STADA Contain?
The active substance in Clozapine STADA is clozapine. Each tablet contains exactly 25 mg of clozapine. This is the pharmacologically active component responsible for the medication's therapeutic effects.
The inactive ingredients (excipients) typically found in clozapine tablet formulations include: lactose monohydrate, maize starch, povidone, magnesium stearate, talc, colloidal anhydrous silica, and other standard pharmaceutical excipients. These ingredients serve as fillers, binders, lubricants, and disintegrants that ensure the tablet holds together during storage yet dissolves properly in the gastrointestinal tract for absorption.
Patients with lactose intolerance should be aware that the tablets may contain lactose monohydrate. While the amount per tablet is small, patients with severe lactose intolerance or rare hereditary conditions such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should consult their doctor before taking this medication.
If you have known allergies or intolerances to any pharmaceutical excipients, discuss this with your pharmacist or prescribing physician before starting treatment. The exact excipient composition can be found in the patient information leaflet included with your specific medication pack, as formulations may vary slightly between manufacturers.
Frequently Asked Questions
Medical References
This article is based on internationally recognized medical guidelines and peer-reviewed research. All medical claims are evidence-based with Level 1A evidence where applicable.
- National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. Updated 2024.
- British Association for Psychopharmacology (BAP). Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the BAP. Journal of Psychopharmacology. 2024.
- Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry. 2016;209(5):385-392.
- Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry. 2003;60(1):82-91.
- European Medicines Agency (EMA). Summary of Product Characteristics: Clozapine. Last updated 2024.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List. 2023.
- Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. 14th edition. Wiley-Blackwell; 2021.
- U.S. Food and Drug Administration (FDA). Clozapine REMS Program. Prescribing Information. 2024.
- De Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research. 2005;76(2-3):135-157.
- Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines. American Journal of Psychiatry. 2017;174(3):216-229.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in psychiatry, psychopharmacology, and clinical pharmacology. Our content follows the GRADE evidence framework and is based on the most current international guidelines.
iMedic Medical Editorial Team - Specialists in psychiatry and psychopharmacology with clinical and academic experience in schizophrenia treatment and clozapine management.
iMedic Medical Review Board - Independent panel following WHO, NICE, EMA, and BAP guidelines. All content undergoes rigorous fact-checking and evidence assessment before publication.
Conflict of interest statement: The iMedic editorial team has no financial relationships with pharmaceutical companies. This content is independently produced with no commercial funding or sponsorship.